HRP20241491T1 - Pripravci i metode za liječenje homocistinurije - Google Patents
Pripravci i metode za liječenje homocistinurije Download PDFInfo
- Publication number
- HRP20241491T1 HRP20241491T1 HRP20241491TT HRP20241491T HRP20241491T1 HR P20241491 T1 HRP20241491 T1 HR P20241491T1 HR P20241491T T HRP20241491T T HR P20241491TT HR P20241491 T HRP20241491 T HR P20241491T HR P20241491 T1 HRP20241491 T1 HR P20241491T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- use according
- mutant polypeptide
- pegylated
- administered
- Prior art date
Links
- 206010020365 Homocystinuria Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229960003237 betaine Drugs 0.000 claims 2
- 102100034976 Cystathionine beta-synthase Human genes 0.000 claims 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/935,690 US9675678B2 (en) | 2013-01-29 | 2015-11-09 | Compositions and methods for treatment of homocystinuria |
| EP21204193.3A EP3998067B1 (en) | 2015-11-09 | 2016-11-09 | Compositions and methods for treatment of homocystinuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241491T1 true HRP20241491T1 (hr) | 2025-01-03 |
Family
ID=58696136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220407TT HRP20220407T1 (hr) | 2015-11-09 | 2016-11-09 | Pripravci i postupci za uporabu u liječenju homocistinurije |
| HRP20241491TT HRP20241491T1 (hr) | 2015-11-09 | 2016-11-09 | Pripravci i metode za liječenje homocistinurije |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220407TT HRP20220407T1 (hr) | 2015-11-09 | 2016-11-09 | Pripravci i postupci za uporabu u liječenju homocistinurije |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11077175B2 (enExample) |
| EP (3) | EP4487914A3 (enExample) |
| JP (2) | JP7009364B2 (enExample) |
| KR (1) | KR102819396B1 (enExample) |
| CN (2) | CN115920016A (enExample) |
| AU (2) | AU2016354030B2 (enExample) |
| BR (1) | BR112018007768A2 (enExample) |
| CA (1) | CA3001625A1 (enExample) |
| CY (1) | CY1125113T1 (enExample) |
| DK (2) | DK3998067T3 (enExample) |
| ES (2) | ES2909914T3 (enExample) |
| FI (1) | FI3998067T3 (enExample) |
| HR (2) | HRP20220407T1 (enExample) |
| HU (2) | HUE058749T2 (enExample) |
| IL (2) | IL258487B2 (enExample) |
| LT (2) | LT3373922T (enExample) |
| MX (1) | MX2018005312A (enExample) |
| NZ (1) | NZ741552A (enExample) |
| PL (2) | PL3998067T3 (enExample) |
| PT (2) | PT3998067T (enExample) |
| RS (2) | RS66106B1 (enExample) |
| SG (1) | SG10201912972SA (enExample) |
| SI (2) | SI3998067T1 (enExample) |
| SM (2) | SMT202400463T1 (enExample) |
| WO (1) | WO2017083327A1 (enExample) |
| ZA (1) | ZA201802376B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| BR112018007768A2 (pt) | 2015-11-09 | 2018-10-23 | Univ Colorado Regents | composições e métodos para tratamento de homocistinúria |
| JP7146897B2 (ja) * | 2017-04-17 | 2022-10-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | ホモシスチン尿症の治療のための酵素補充療法の最適化 |
| DK3990005T3 (da) * | 2019-06-26 | 2025-12-08 | Travere Therapeutics Switzerland Gmbh | Pegyleret cystathioninbetasynthase til enzymterapi til behandling af homocystinuri |
| EP4025243A4 (en) * | 2019-09-03 | 2023-09-27 | Travere Therapeutics Switzerland GmbH | CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS555429A (en) * | 1978-06-23 | 1980-01-16 | Nissan Motor Co Ltd | Pressure regulator for fuel injection type gasoline engine |
| JPS5576559A (en) | 1978-12-01 | 1980-06-09 | Chiyou Lsi Gijutsu Kenkyu Kumiai | Electron beam fine adjusting device |
| US5656425A (en) | 1993-08-17 | 1997-08-12 | Regents Of The University Of Colorado | Screening for mutations by expressing cDNA segments |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| EP1221615A2 (en) | 1995-04-25 | 2002-07-10 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| US5705151A (en) | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| CN100335503C (zh) | 1998-04-28 | 2007-09-05 | 应用研究系统Ars股份公司 | 多元醇干扰素β偶联物 |
| US6174696B1 (en) | 1999-11-12 | 2001-01-16 | Genzyme Corporation | Method for the determination of homocysteine |
| WO2001002600A2 (en) | 1999-07-06 | 2001-01-11 | General Atomics | Detection of analytes using attenuated enzymes |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| US20030091543A1 (en) | 2001-10-26 | 2003-05-15 | Klein Matthew B. | Therapeutic cell preparation grafts and methods of use thereof |
| US7485307B2 (en) | 2002-06-17 | 2009-02-03 | The Regents Of The University Of Colorado | Human cystathionine β-synthase variants and methods of production thereof |
| GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| EP1396537A1 (en) * | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| US20050036981A1 (en) | 2003-07-31 | 2005-02-17 | Shigeo Yagi | USE OF PLP WITH PEG-rMETase IN VIVO FOR ENHANCED EFFICACY |
| CN1552905A (zh) | 2003-12-18 | 2004-12-08 | 中国农业科学院茶叶研究所 | 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片 |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| US20070010492A1 (en) | 2005-07-11 | 2007-01-11 | Generale Robert J | Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
| EP1878739A1 (en) | 2006-07-14 | 2008-01-16 | LEK Pharmaceuticals D.D. | One step IMAC (MCAC) purification of proteins |
| JP6041454B2 (ja) * | 2007-03-15 | 2016-12-07 | 株式会社 Ｄｎａセキュリティー研究所 | Ｄｎａ含有インク組成物 |
| JP5074146B2 (ja) | 2007-03-30 | 2012-11-14 | オリンパス株式会社 | カプセル型医療装置 |
| CN101322840A (zh) | 2008-05-28 | 2008-12-17 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 一种人胱硫醚β-合成酶重组蛋白及应用 |
| EP2470568A2 (en) | 2009-08-29 | 2012-07-04 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| WO2011097381A2 (en) | 2010-02-04 | 2011-08-11 | The Board Of Regents Of Use University Of Texas System | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof |
| CA2803668A1 (en) | 2010-07-01 | 2012-01-05 | Isis Innovation Limited | Treatment of cognitive disorders |
| US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| WO2015033279A1 (en) * | 2013-09-04 | 2015-03-12 | Mahesh Kandula | Compositions and methods for the treatment of homocystinuria |
| EP3325496B1 (en) | 2015-07-24 | 2024-02-07 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
| BR112018007768A2 (pt) | 2015-11-09 | 2018-10-23 | Univ Colorado Regents | composições e métodos para tratamento de homocistinúria |
| JP7146897B2 (ja) * | 2017-04-17 | 2022-10-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | ホモシスチン尿症の治療のための酵素補充療法の最適化 |
| JP7002314B2 (ja) * | 2017-12-13 | 2022-02-10 | 株式会社ブリヂストン | 空気入りタイヤ |
| DK3990005T3 (da) | 2019-06-26 | 2025-12-08 | Travere Therapeutics Switzerland Gmbh | Pegyleret cystathioninbetasynthase til enzymterapi til behandling af homocystinuri |
| EP4025243A4 (en) | 2019-09-03 | 2023-09-27 | Travere Therapeutics Switzerland GmbH | CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS |
-
2016
- 2016-11-09 BR BR112018007768A patent/BR112018007768A2/pt not_active Application Discontinuation
- 2016-11-09 IL IL258487A patent/IL258487B2/en unknown
- 2016-11-09 CA CA3001625A patent/CA3001625A1/en active Pending
- 2016-11-09 HR HRP20220407TT patent/HRP20220407T1/hr unknown
- 2016-11-09 PL PL21204193.3T patent/PL3998067T3/pl unknown
- 2016-11-09 SM SM20240463T patent/SMT202400463T1/it unknown
- 2016-11-09 HR HRP20241491TT patent/HRP20241491T1/hr unknown
- 2016-11-09 SG SG10201912972SA patent/SG10201912972SA/en unknown
- 2016-11-09 HU HUE16864878A patent/HUE058749T2/hu unknown
- 2016-11-09 WO PCT/US2016/061050 patent/WO2017083327A1/en not_active Ceased
- 2016-11-09 PT PT212041933T patent/PT3998067T/pt unknown
- 2016-11-09 DK DK21204193.3T patent/DK3998067T3/da active
- 2016-11-09 ES ES16864878T patent/ES2909914T3/es active Active
- 2016-11-09 ES ES21204193T patent/ES2994256T3/es active Active
- 2016-11-09 EP EP24199181.9A patent/EP4487914A3/en active Pending
- 2016-11-09 AU AU2016354030A patent/AU2016354030B2/en active Active
- 2016-11-09 RS RS20241229A patent/RS66106B1/sr unknown
- 2016-11-09 DK DK16864878.0T patent/DK3373922T3/da active
- 2016-11-09 LT LTEPPCT/US2016/061050T patent/LT3373922T/lt unknown
- 2016-11-09 LT LTEP21204193.3T patent/LT3998067T/lt unknown
- 2016-11-09 EP EP16864878.0A patent/EP3373922B1/en active Active
- 2016-11-09 KR KR1020187013230A patent/KR102819396B1/ko active Active
- 2016-11-09 PL PL16864878T patent/PL3373922T3/pl unknown
- 2016-11-09 SI SI201631858T patent/SI3998067T1/sl unknown
- 2016-11-09 SI SI201631487T patent/SI3373922T1/sl unknown
- 2016-11-09 MX MX2018005312A patent/MX2018005312A/es unknown
- 2016-11-09 CN CN202211006580.6A patent/CN115920016A/zh active Pending
- 2016-11-09 RS RS20220308A patent/RS63070B1/sr unknown
- 2016-11-09 JP JP2018523444A patent/JP7009364B2/ja active Active
- 2016-11-09 NZ NZ741552A patent/NZ741552A/en unknown
- 2016-11-09 HU HUE21204193A patent/HUE068830T2/hu unknown
- 2016-11-09 SM SM20220151T patent/SMT202200151T1/it unknown
- 2016-11-09 IL IL302198A patent/IL302198A/en unknown
- 2016-11-09 CN CN201680076275.0A patent/CN108472277A/zh active Pending
- 2016-11-09 PT PT168648780T patent/PT3373922T/pt unknown
- 2016-11-09 EP EP21204193.3A patent/EP3998067B1/en active Active
- 2016-11-09 FI FIEP21204193.3T patent/FI3998067T3/fi active
-
2018
- 2018-04-11 ZA ZA201802376A patent/ZA201802376B/en unknown
-
2020
- 2020-03-20 US US16/824,931 patent/US11077175B2/en active Active
-
2021
- 2021-06-29 US US17/362,633 patent/US11771745B2/en active Active
-
2022
- 2022-01-12 JP JP2022002966A patent/JP7482914B2/ja active Active
- 2022-04-04 CY CY20221100254T patent/CY1125113T1/el unknown
- 2022-12-12 AU AU2022287540A patent/AU2022287540B2/en active Active
-
2023
- 2023-08-23 US US18/454,701 patent/US12194082B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241491T1 (hr) | Pripravci i metode za liječenje homocistinurije | |
| PH12020551691A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| PH12020551066A1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| MX353608B (es) | Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo. | |
| PE20241305A1 (es) | Analogos de amilina | |
| NZ749962A (en) | Pegylated porcine interferon and methods of use thereof | |
| AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
| PE20191206A1 (es) | Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos musculares | |
| JOP20190146A1 (ar) | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد | |
| HK1247822A1 (zh) | 用於活性剂口服给药的制剂 | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| PH12020500321A1 (en) | Amino acid compositions for the treatment of liver disease | |
| MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| PH12022550007A1 (en) | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX386216B (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2022001565A (es) | Formas solidas de un estimulador de guanilato ciclasa soluble (sgc). | |
| JOP20220110A1 (ar) | ناهضات مستقبل npy2 | |
| CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
| BR112022007776A2 (pt) | Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína | |
| JP2015517484A5 (enExample) |